Hypertension is often accompanied by a variety of metaabnormal more atherogenic LDL cholesterol particle. Dyslipidemia interacts with associated hemodynamic bolic abnormalities. These metabolic abnormalities include insulin resistance, dyslipidemia and abnormali-(ie, hypertension) and metabolic (ie, increased platelet aggregation and PAI-1 levels) in a multiplicative manner ties of the coagulation-fibrinolytic system predisposing to a procoagulent state. The nexus for all of these potentiating cardiovascular and renal disease. Accordingly, lipid therapy should be aggressive to attenuate abnormalities may be central (visceral) obesity. The dyslipidemia accompanying hypertension consists of low these medical complications of essential hypertension. HDL cholesterol, elevated triglyceride levels and an
Introduction
those persons with type II diabetes and impaired Ischemic heart disease (IHD) impacts more than 12 glucose tolerance had higher triglycerides and lower million people, and remains the highest cause of HDL compared with normal controls. 13 Similar death in the US. Lipid abnormalities, cigarette observations have been made in other populations. 14 smoking and hypertension are known modifiable Genetics studies, including twin, parent-child studrisk factors for IHD.
1-7 Furthermore, the risk for IHD ies, large scale family, and candidate gene studies is markedly increased with multiple risk factors, provide substantial evidence for a genetic basis for especially if diabetes is one of those risk factors. 4,5,8- the relationship between hypertension/diabetes and 12 Diabetes is often accompanied by hypertension, other accompanying metabolic abnormalities.
11, [15] [16] [17] which is twice as frequent in individuals with this There is higher heritability in estimates twins than metabolic disorder as in those without. [9] [10] [11] This artiin pedigrees for blood pressure (BP), very low dencle reviews the impact of dyslipidemia and other sity lipoproteins (VLDL), LDL, and BMI. 15 In one metabolic abnormalities that often accompany diastudy it was estimated that 70% of adults with betes mellitus and hypertension, and therapeutic hypertension before age 55 have siblings or parents strategies which address metabolic as well as hemowith hypertension, and 12% of all hypertensive dynamic abnormalities.
patients have familial dyslipidemic hypertension. 17 Thus, both hypertension and dyslipidemic conditions appear to have a genetic basis, and both have Genetic basis for lipid abnormalities been linked to insulin resistance. 11 The genetic accompanying diabetes/hypertension Hypertensive persons matched for age and body and apo B-100 through a sulfhydryl bond). Apo(a) small dense LDL particles) is closely linked to the LDL receptor and to the insulin receptor locus. [17] [18] [19] is highly homologous to plasminogen but without its protease activity. 31, 32 Accordingly, it does not Indeed, in coronary sibships, three-fourths of those with early coronary disease have lipid abnormalities possess the ability to catalyze the conversion of fibrinogen and fibrin to degradable products. 31, 32 associated with the familial dyslipidemic hypertension syndrome. 11, 17 Sequencing of DNA has shown L(a) potentiates thrombosis because it inhibits the binding of plasminogenic binding proteins on the a point mutation for the enzyme lipoprotein lipase that contributes to high VLDL/low HDL and posssurface of endothelial cells, thus inhibiting the conversion of plasminogen to plasmen and thus ibly hypertension. 17 In an investigation examining the relationship between HDL cholesterol and the fibrinogen and fibrin degradation. Lp(a) also inhibits fibrinolysis, possibly via fibrin binding attributable variable region flanking the human insulin gene, one class of alleles was associated with a family history to the kringle repeats of apo(a), Lp(a) may delay thrombolysis and contribute to the progression of of both diabetes and IHD. 18 In children from the Bogalusa cohort, postprandial insulin levels were atherosclerotic plaques. [31] [32] [33] [34] Plasma levels of Lp(a) have been observed to be elevated with increasing positively correlated with fasting serum cholesterol and VLDL. 20 Thus, there is mounting evidence for a age, LDL-cholesterol levels 33 and hyperglycemia. 34 Similar to LDL, Lp(a) can undergo oxidative modigenetic basis for the association of insulin resistance and dyslipidemia. 21 In turn, both of these abnormalification and has been localized in atherosclerotic lesions, 33 suggesting a direct participation. 5 While it ties are associated with hypertension and type II diabetes mellitus.
9-12, [22] [23] [24] seems likely that lowering of Lp(a), could decrease atherosclerotic vascular disease risk, currently there are no data to support this notion. Niacin and postElevated VLDL and serum triglycerides menopausal estrogen therapy, but not other lipid High serum triglyceride levels are associated with therapies have been demonstrated to lower increased IHD risk, 21, 25 and often elevated in associLp(a), 5,31,32 but additional investigation is needed to ation with insulin resistance. 21 Viseral or 'android' determine the relevance of this effect. obesity is associated with insulin resistance, elevated VLDL, reduced HDL and an increased propenPost-translational modification of lipoproteins sity to IHD. [22] [23] [24] [25] [26] Compared with adipocytes located associated with diabetes mellitus peripherally (ie, gluteofemoral), visceral adipocytes display greater sensitivity to lipolytic hormones. 27 Hyperglycemia contributes to acceleration of atheroThe consequent increased lipolysis in visceral obessclerosis, in part, by resulting in glycooxidation of ity, in turn, causes increased free fatty acid (FFA) lipoprotein particles (Table 1) . 4, 5, [35] [36] [37] In the diabetic turnover into the portal and systemic circulations.
state, the generation of reactive oxygen species Delivery of increased FFA to the liver inhibits hep-(ROS) or free radicals by vascular intimal macroatic clearance of circulating insulin, and stimulates phages and vascular smooth muscle cells (VSMC) hepatic glycogenesis as well as synthesis and release results in oxidative modification of lipoproteins and of triglyceride-rich lipoprotein (VLDL).
11,21
vascular structural proteins. Oxidation of LDL modiIncreased levels of FFA are, in turn, associated with fies not only the fatty acid and lipoprotein content reduced insulin sensitivity. 28 This relationship is of this particle, but also the amino acid side chains explained by the observation that increases in FFA of apo B, analogous to the modification produced by oxidation elevated the mitochondrial ratio of acetylacetylation. 35 As a result, oxidized LDL (ox-LDL) is CoA to CoA, which suppresses pruvate dihydrono longer recognized by the classical LDL receptor, genase (PDH) directly, and phosphofructo 1-kinase but by macrophage scavenger receptors which and hexokinase activities indirectly via citrate and enhances ox-LDL uptake into vascular tissue. 35, 36 glucose 6-phosphate (C-6-P) accumulation, and Once taken up by foam cells, ox-LDL is poorly resultant inhibition of glucose uptake and oxidegraded leading to further accumulation. Ox-LDL dation. 28 Further, as a result of the consequent is also toxic to endothelial cells, altering both strucdecrease in insulin sensitivity, there is decreased ture and function. 35, 36 Ox-LDL also stimulates the activity of endothelial bound lipoprotein lipase in production of chemoattracts thereby increasing skeletal muscle and adipocytes, and it is this lipomigration and binding of monocytes to damaged protein lipase that is responsible for the metabolism endothelium. In addition, antibodies to ox-LDL may of triglyceride rich particles. Thus, triglyceride levbe involved in the latter stages of atheroma formaels increase because of increased hepatic production tion. 35 of triglyceride-enriched lipoproteins coupled with Glycosylation, the non-enzymatic linkage of glureduced peripheral metabolism of VLDL. 11, 21 cose to proteins also contributes to glycemiaBecause of inefficient triglyceride metabolism, HDL induced alterations of lipoproteins and vascular levels demonstrate a parallel fall. 11, 21 structural proteins 4,5,10-12,36,37 (Table 2 ). Similar to ox-LDL, glycated LDL, in part through glycation of Lipoprotein (a) (Lp(a)) in diabetes mellitus the apo B moiety, is taken up by a foam cell scavenger pathway and enhances atherogenity in diabetic Plasma levels of Lp(a) have been reported to be elevated in diabetic individuals particularly those with persons. 36, 37 Compared to normal LDL, glycated LDL Clot formation is attenuated by specific factors that inhibit one or more clotting factors (ie, TNF-␣ indicates tumor necrosis factor-a; PDGF, platelet-derived antithrombin III (AIII), protein C and S), and by the growth factor. fibrinolytic system both of which are deficient in individuals with diabetes mellitus and hypertension.
4,5,10-12,38-50 ATIII, which inhibits thrombin, Xa, sequestered in the arterial intima has a greater proIXa, and XIIa, has been reported to be deficient in pensity to become bound by glucose-mediated diabetic persons, particularly those in poor metacrosslinks to local matrix proteins. 55 These observations are related to the fact that PAI is the major plasma inhibitor of plasminHypercoagulation and disturbances of the ogen activators which convert plasminogen to the fibrinolytic system have been reported in association active proteolytic/fibrinolytic enzyme plasmin.
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with diabetes mellitus/hypertension and associated dyslipidemias and cardiovascular disease (Table  3) .
4-12,38-50
A procoagulent state in diabetes and hypertension is mediated, in part, by higher than Metabolic abnormalities and endothelial normal levels of coagulation factors. Thrombus gendysfunction in diabetes mellitus and hypertension eration and enlargement depends on the transformThere is an array of functional and anatomical ation of fibrinogen to fibrin. 5 This process occurs in abnormalities of the vascular endothelium associathree phases: proteolysis, polymerization, and stabited with diabetes mellitus, hypertension and dysliplization. Thrombin, an enzyme derived from the cidemia (Table 4) . 5,10-12,22,23,56 Both hyperglycemia terminal portion of prothrombin, is necessary for all and dyslipidemia have independent toxic effects on three phases. It is mainly responsible for four pivotal the vascular endothelium. Vascular segments from steps: (1) potentiation of the tenase (factor Xa diabetic rats demonstrate impaired endotheliumactivity in the presence of factor VIIIa) and prodependent (nitric oxide (NO) mediated) relaxation, thrombinase complexes; (2) conversion of fibrinowhich can also be produced by incubating normal gen to fibrin monomers; (3) exposure of fibrin vessels in a high glucose media. 57 Hyperglycemia monomer polymerization sites; and (4) factor XIIIaactivates protein kinase C in endothelial cells, mediated covalent crosslinking of fibrin polymers.
which may account for increased production of vasoconstrictor prostaglandin, endothelia and angi- involved in collagen synthesis. 45, 58 Elevated glucose levels also delays replication and increases death of Figure 1 In the intrinsic system endothelial damage or dysfunction activates factor XII, when then (in the presence of high molecular weight kininogen) converts prekallikrein into kallikrein, which in turn converts fibrin-bound plasminogen into plasmin. The major inhibitor of this system includes PAI-1, which inhibits XIIa conversation of prekallikrein into kallikrein, and complement inactivator, which inhibits activation of plasminogen. thelial damage can result in release of growth factors (ie, endothelia, platelet derived and insulin-like endothelial cells, 60 in part, by enhancing glycooxidgrowth factor) which can enhance mesangial cell ation. 36 proliferation and matrix overproduction.
12, [65] [66] [67] [68] Hypercholesterolemia, and perhaps hypertriglyThese metabolic abnormalities may also interfere ceridemia, impair endothelium-dependent relaxwith the production of NO and vasodilatory prostaation. 61, 62 In diabetes there is decreased conversion glandins which inhibit mesangial cell growth and of cholesterol ester-enriched VLDL to LDL, and the matric production. 12,69 Thus, it is not surprising that resulting large and abnormal cholesterol estertreatment of hyperglycemia 70 and hypercholesteroenriched VLDL is injurious to endothelial cells follemia 67, 68 favorably impact on diabetic glomerulowing receptor-mediated uptake. 63 Recently, it has losclerosis. been reported that in hypertension not associated with impaired carbohydrate metabolism or dyslipidemia, there is preservation of endothelium-depenDyslipidemia therapy dent vasodilation. 64 Thus, it appears to be the metaAggressive therapy of hypercholesterolemia (ie, LDL bolic abnormalities accompanying diabetes and Ͼ130 mg/dl) in persons with established ischemic hypertension which play a major role in develop-IHD or other atherosclerotic disease (secondary ment of endothelial dysfunction. prevention) is well supported by data from several recent studies. [71] [72] [73] [74] These clinical trials have shown Contributions of metabolic abnormalities to renal that lowering of LDL cholesterol in persons with glomerular disease established atherosclerotic disease reduces angiographic progression of coronary artery disease, carPathophysiologically, diabetic glomerulosclerosis has many features analogous to vascular atherosclerdiovascular events and total mortality. Further, a recently reported study, 75 using an HMG-CoA mation in balloon-injured carotid arteries can be abolished by a bradykin antagonist or by inhibition reductase inhibitor, demonstrated a decrease in IHD events and total mortality in individuals with sigof NO synthesis using N-nitro-L-arginine methyl ester (L-NAME). Other anti-atherogenic properties of nificant risk factors including hypercholesterolima but without established disease (primary ACE inhibitors may relate to blockade of Ang II stimulated protein synthesis and proto-oncogene prevention). Therefore, it is reasonable to extrapolate to the diabetic patient, especially those with expression ( Figure 2) . [77] [78] [79] [80] [81] [82] [83] Nevertheless, more data are needed to determine if these protective experihypertension, as a 'high risk' patient that may require very aggressive primary prevention therapy mental effects of ACE inhibitors extend to human disease. Current data is promising since ACE inhibifor their dyslipidemia, as well as their hyperglycemia 70 
